Method of Treatment
AssigneeHaemaLogix Pty Ltd
InventorsRosanne Dunn, Ben R. Herbert, Edmond J. Breen
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to therapeutic combinations comprising an anti-KMA antibody and a proteasome inhibitor for the treatment of multiple myeloma. The present disclosure also relates to methods of treating multiple myeloma in subjects with high serum cytokine levels.
Claims49
A method of treating multiple myeloma in a subject in need thereof, the method comprising administering to the subject an anti-KMA antibody and a proteasome inhibitor.
A therapeutic combination comprising a proteasome inhibitor and an anti-KMA antibody, the combination being provided for simultaneous or sequential administration.
A method of treating multiple myeloma in a subject, the method comprising selecting a subject who has high serum levels of one or more of the following factors relative to control serum levels:
- hepatocyte growth factor (HGF), macrophage inhibitory factor (MIF), CCL27, G-CSF, CXCL9, and CXCL10;
- and administering to the subject an anti-KMA antibody.
Use of a proteasome inhibitor and an anti-KMA antibody defined by any one of the preceding claims in the manufacture of a medicament for the treatment of multiple myeloma.
A proteasome inhibitor and an anti-KMA antibody defined by any one of the preceding claims for use in the treatment of multiple myeloma.
Dependencies are inferred from the claim text.